A spicamycin derivative (KRN5500) provides neuropathic pain relief in patients with advanced cancer: A placebo-controlled, proof-of-concept trial

Journal of Pain and Symptom Management

Volumn 43, Issue 4, 2012, Pages 679-693

  Weinstein, Sharon M ^a,b   Abernethy, Amy P ^c   Spruill, Susan E ^d   Pike, Isadore M ^e   True Kelly, Andrea ^f   Jett, Linda G ^g  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Applied Statistics and Consulting   (United States)

^e Izzy Pike MD Consulting ^*  (United States)

^f ATK Clinical Consulting   (United States)

^g DARA BioSciences   (United States)

Author keywords

allodynia; cancer; KRN5500; Neuropathic pain; spicamycin

Indexed keywords

6 [4 DEOXY 4 (2,4 TETRADECADIENOYLGLYCYLAMINO) GLYCERO BETA MANNOHEPTOPYRANOSYLAMINO] 9H PURINE; PLACEBO;

ADULT; ADVANCED CANCER; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; INFESTATION; MALE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NUTRITIONAL DISORDER; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SINGLE DRUG DOSE; SKIN DISEASE; TREATMENT OUTCOME; VOMITING;

ADULT; ANALGESICS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEURALGIA; PAIN MEASUREMENT; PILOT PROJECTS; PLACEBO EFFECT; PURINE NUCLEOSIDES; SPIRAMYCIN; TERMINAL CARE; TREATMENT OUTCOME;

EID: 84859218108     PISSN: 08853924     EISSN: 18736513     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2011.05.003     Document Type: Article

References (34)

1. H. Merskey, and N. Bogduk Classification of chronic pain 1994 IASP Press Seattle, WA
2. R.-D. Treede, T.S. Jensen, and J.N. Campbell Neuropathic pain: redefinition and a grading system for clinical and research purposes Neurology 70 2008 1630 1635 (Pubitemid 351620320)
3. S. Olsen Providing an enhanced perspective on neuropathic pain. Consulting and marketing report 2002 WWMR, Inc. San Mateo, CA Available from http://www.highbeam.com/publications/pr-newswire-p3672/aug-27-2002/2 Accessed September 28, 2011
4. M. Pappagallo The neurological basis of pain 2005 McGraw-Hill, Co. New York
5. M.N. Baliki, P.Y. Gehe, A.V. Apkarain, and D.R. Chialvo Beyond feeling: chronic pain hurts the brain, disrupting the default mode network dynamics J Neurosci 28 2008 1398 1403 (Pubitemid 351231512)
6. A. Kuchinad, P. Schweinhardt, P. Wood, B.A. Chizh, and M.C. Bushnell Accelerated brain gray-matter loss in fibromyalgia patients: premature aging of the brain? J Neurosci 27 2007 4004 4007 (Pubitemid 46597143)
7. S. Arner, and B. Arner Differential effect of epidural morphine in the treatment of cancer-related pain Acta Anaesthesiol Scand 29 1985 32 36 (Pubitemid 15191109)
8. N.I. Cherny, H.T. Thaler, and H. Friedlander-Klar Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled single-dose studies Neurology 44 1994 857 861 (Pubitemid 24158800)
9. G. Garcia de Paredes, F. del Moral Gonzalez, and M. Martinez del Prado First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. Results of the On study Ann Oncol 22 2011 924 930
10. S. Grond, L. Radbruch, and T. Neuser Assessment and treatment of neuropathic cancer pain following WHO guidelines Pain 79 1999 15 20 (Pubitemid 29012430)
11. World Health Organization Cancer pain relief 1986 World Health Organization Geneva, Switzerland
12. S.M. Gadgeel, R.R. Bionpally, and L.K. Heilbrun A phase 1 clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase 1 accelerated titration "2B" design Invest New Drugs 21 2003 63 74 (Pubitemid 36628486)
13. J. Supko, J. Eder, and D. Ryan Phase 1 clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors Clin Cancer Res 9 2003 5178 5186 (Pubitemid 37413567)
14. N. Yamamoto, T. Tamura, and Y. Kamiya Phase 1 and pharmacokinetic study of KRN5500, a spicamycin derivative, for patients with advanced solid tumors Jpn J Clin Oncol 33 2003 302 308 (Pubitemid 43115257)
15. D. Borsook, and A. Edward Antineuropathic effects of the antibiotic derivative Spicamycin, KRN5500 Pain Med 5 2004 104 108 (Pubitemid 38404450)
16. S. Abdi, N. Vilassova, I. Decosterd, N. Feroz, and D. Borsook The effects of KRN5500, a spicamycin derivative, on neuropathic and nociceptive pain models in rats Anesth Analg 91 2000 955 999
17. L. DiLorenzo, L. Kobierski, K.A. Moore, and D. Borsook A water soluble synthetic Spicamycin derivative (San-Gly) decreases mechanical allodynia in a rodent model of neuropathic pain Neurosci Lett 330 2002 37 40 (Pubitemid 35245764)
18. L. Kobierski, S. Abdi, L. DiLorenzo, N. Feroz, and D. Borsook A single intravenous injection of KRN5500 (antibiotic spicamycin) produces long-term decreases in multiple sensory hypersensitivities in neuropathic pain Anesth Analg 97 2003 174 182 (Pubitemid 36736557)
19. K. Skare, and W. Sietsema From serendipity to science Good Clin Pract J 12 2005 1 4
20. U.S. Food and Drug Administration. Code of Federal Regulations Title 21. IND safety reports. 21CFR312.32.
21. S. Krause, and M. Backonja Development of a neuropathic pain questionnaire Clin J Pain 19 2003 306 314 (Pubitemid 37075671)
22. C. Cleeland, and K. Ryan Pain assessment: global use of the Brief Pain Inventory Ann Acad Med 23 1994 129 138
23. D. Karnofsky, W. Abelman, L. Craver, and J. Burchenal The use of nitrogen mustards in the palliative treatment of carcinoma Cancer 1 1948 634 656
24. J. Ware, M. Kosinski, D.M. Tuner-Bowker, and B. Gandek Version 2 of the SF-12 health survey 2002 Quality Metric, Inc. Boston, MA
25. F. Hausheer, and K. Foley Cancer neuropathic pain: overview of current status and future objectives Oncologist 15 Suppl 2 2010 1 2
26. M. Lema, K. Foley, and F. Hausheer Types and epidemiology of cancer-related neuropathic pain: the intersection of cancer pain and neuropathic pain Oncologist 15 Suppl 2 2010 3 8
27. C. Cleeland, J. Farrar, and F. Hausheer Assessment of cancer-related neuropathy and neuropathic pain Oncologist 15 Suppl 2 2010 13 18
28. Material Safety Data Sheets for monoethanolamine. Available from http://www.sciencelab.com/msds.php?msdsId=9922885. Accessed September 11, 2011.
29. Material Safety Data Sheets for N, N-dimethylacetamide. Available from http://www.caledonlabs.com/upload/msds/3900-1e.pdf. Accessed September 11, 2011.
30. J. Younger, R. McCue, and S. Mackey Pain outcomes: a brief review of instruments and techniques Curr Pain Headache Rep 13 2009 39 43
31. M. Backonja, and R. Glanzman Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials Clin Ther 25 2003 81 104 (Pubitemid 36206739)
32. R. Dworkin, D. Turk, and N. Katz Evidence-based clinical trial design for chronic pain pharmacotherapy: a blueprint for ACTION Pain 152 2011 S107 S115
33. R. Dworkin, J. Katz, and M. Gitlin Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain Neurology 65 Suppl 4 2005 S7 S19
34. R. Rao, P. Flynn, and J. Sloan Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, no1c3 Cancer 112 2008 2801 2808